CAJ | 학술논문

在过去的2011年,国际糖尿病联盟(IDF)、美国内分泌医师协会(AACE)、中华医学会糖尿病学分会及内分泌学分会等组织,针对糖尿病的临床诊治、实验室检测及并发症的治疗等颁布了一些指南和共识;关于中国人糖尿病血管病变特点及糖尿病死因方面也有新的研究发布;同时,对于几种降糖药物的安全性问题,美国食品与药品管理局(FDA)和欧洲药品管理委员会(EMEA)也发布了声明.这些对于规范临床诊治及用药有重要意义.
재과거적2011년,국제당뇨병련맹(IDF)、미국내분비의사협회(AACE)、중화의학회당뇨병학분회급내분비학분회등조직,침대당뇨병적림상진치、실험실검측급병발증적치료등반포료일사지남화공식;관우중국인당뇨병혈관병변특점급당뇨병사인방면야유신적연구발포;동시,대우궤충강당약물적안전성문제,미국식품여약품관리국(FDA)화구주약품관리위원회(EMEA)야발포료성명.저사대우규범림상진치급용약유중요의의.
During the past year of 2011,International Diabetes Federation ( IDF),American Association of Clinical Endocrinologists ( AACE),Chinese Diabetes Society,and Chinese Society of Endocrinology,etc had published some guidelines and consensuses on clinical diagnosis,treatment,laboratory test,and complication therapy of diabetes.Characters of diabetic angiopathy in Chinese and death cause of diabetes were also announced by several new studies.Meanwhile,Food and Drug Administration ( FDA ) and The European Agency for the Evaluation of Medicinal Products(EMEA) declared their statements on safety of several hypoglycemic agents.These guidelines and consensuses will play key roles on standard clinical diagnosis,treatment,and medication.